PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Helps investors judge whether earnings growth is driven by sustainable operations or temporary factors. Consistent, organic income expansion can justify a higher intrinsic value for patient, long-term investors.
No Data
No Data available this quarter, please select a different quarter.
-100.00%
Both companies reducing costs. Martin Whitman would check industry efficiency trends.
100.00%
Similar gross profit growth to GNPX's 100.00%. Walter Schloss would investigate industry dynamics.
No Data
No Data available this quarter, please select a different quarter.
10.75%
R&D growth less than half of GNPX's 65.38%. David Dodd would verify if efficiency advantage is sustainable.
-21.32%
Both companies reducing G&A. Martin Whitman would check industry cost trends.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
1.47%
Operating expenses growth while GNPX reduces costs. John Neff would investigate differences.
1.47%
Total costs growth while GNPX reduces costs. John Neff would investigate differences.
No Data
No Data available this quarter, please select a different quarter.
6.88%
D&A growth while GNPX reduces D&A. John Neff would investigate differences.
-1.39%
EBITDA decline while GNPX shows 33.67% growth. Joel Greenblatt would examine position.
No Data
No Data available this quarter, please select a different quarter.
-1.47%
Operating income decline while GNPX shows 33.67% growth. Joel Greenblatt would examine position.
No Data
No Data available this quarter, please select a different quarter.
-3.00%
Both companies reducing other expenses. Martin Whitman would check industry patterns.
-1.89%
Pre-tax income decline while GNPX shows 33.56% growth. Joel Greenblatt would examine position.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-1.89%
Net income decline while GNPX shows 33.56% growth. Joel Greenblatt would examine position.
No Data
No Data available this quarter, please select a different quarter.
2.63%
EPS growth below 50% of GNPX's 59.00%. Michael Burry would check for structural issues.
2.63%
Diluted EPS growth below 50% of GNPX's 59.00%. Michael Burry would check for structural issues.
3.22%
Share count reduction exceeding 1.5x GNPX's 61.88%. David Dodd would verify capital allocation.
3.22%
Diluted share reduction exceeding 1.5x GNPX's 61.88%. David Dodd would verify capital allocation.